PMHNP Practice Authority in Oklahoma: Independence, Physician Agreements and Schedule II

AANP's May 2026 map classes Oklahoma as restricted.

The label is AANP's advocacy classification; the legal fact behind it sits in the Nursing Practice Act's definitions.

Supervision attaches to prescribing, not to the licence: the supervising-physician and supervision definitions apply to a Certified Nurse Practitioner, Clinical Nurse Specialist, or Certified Nurse-Midwife who has not obtained independent prescriptive authority.

And supervision is defined as availability, not presence: the physician must be reachable by direct contact, telecommunications, or other appropriate electronic means for consultation, assistance with medical emergencies, or patient referral, subject to a defined formulary.

Since November 1, 2025, that supervisory condition has an exit — 6,240 qualifying hours — covered in the next section.

The exit is 59 O.S. § 567.4c (Laws 2025, c.

340, eff.

Nov.

1, 2025).

An APRN recognized by the Board as a Certified Nurse Practitioner, Clinical Nurse Specialist, or Certified Nurse-Midwife who has completed the statutory minimum — six thousand two hundred forty (6,240) clinical practice hours with prescriptive authority supervised by a physician — may apply for authority to prescribe and order independent of supervision.

It unlocks all prescribing the recognition otherwise allows, without the agreement.

It does not unlock Schedule I and II, barred for independent prescribers too.

Hours earned before the act's effective date count (§ 567.4c(B)(2)).

The recognition is specific to each APRN role and specialty certification held, an APRN cannot hold independent recognition for one licence and supervised recognition for another, and the application itself adds an hours attestation, the graduate-degree requirement and the 45-hour pharmacotherapeutics CE (Form RS-07b).

Nothing in the sources read addresses out-of-state hours toward the 6,240 — confirm with the Board.

Renewal takes at least forty (40) hours of Category I continuing medical education per two-year period (§ 567.4a(4)).

While supervised, the recognition rests on a written supervision agreement that must meet the requirements of 'Section 4 of this act' — the 2025 act's agreement provisions, which were not among the sources read, so the agreement's full required contents are not stated here.

What the read text does fix: the agreement is part of the initial application and the renewal application submitted to the Board, and changes must be filed with the Board within thirty (30) days, effective on filing (§ 567.4a(1)).

The Board's rules require the supervising physician's written statement to identify a mechanism for appropriate referral, consultation, and collaboration, and for availability of communication through direct contact, telecommunications, or other appropriate electronic means (OAC 485:10-16-3(3)).

For an associate choosing a supervisor, the statute's availability definition reads as availability, not on-site presence — but the unread agreement provisions could say more, so confirm the terms with the Board before relying on a distance arrangement.

No physician-to-APRN ratio, chart-review percentage or meeting frequency was located in the sources read.

The controlled-substances statute authorizes an advanced practice nurse recognized to prescribe, subject to medical direction by a supervising physician, to prescribe and administer Schedule III, IV and V only (63 O.S. § 2-312(C)); the Schedule I and II bar for independent prescribers rests on the Board's own documents: the Exclusionary Formulary states it flatly, and its October 30, 2025 independent-authority form repeats it for independent prescribers.

So an outpatient Oklahoma PMHNP, supervised or independent, cannot prescribe Schedule II ADHD stimulants; the prescriber who can is a physician or, under § 2-312(E), a physician assistant.

Schedules III–V cap at a 30-day supply.

Registration is twofold, DEA plus the Oklahoma Bureau of Narcotics and Dangerous Drugs Control (OBNDD); the independent-authority form adds that if either lapses, the APRN must cease prescribing Schedule III–V (Form RS-07b).

The formulary also bars clozapine outside its narrow REMS exception, and lists ketamine and propofol with no exception.

The 2025 edition of § 2-312 could not be retrieved; the Board's post-act formulary and form are the evidence the bar survived the 2025 act.

A PMHNP registers with the DEA as a mid-level practitioner, and that registration covers only what Oklahoma lets the APRN prescribe — the DEA form listing Schedules II–V does not override Oklahoma's Schedule II bar.

Modality is not the barrier: the Board's rules allow an APRN to prescribe in writing, orally, or by other means of telecommunication, for drugs not on the exclusionary formulary (OAC 485:10-16-5(a)).

Telehealth changes nothing about the drug list: the DEA and HHS telemedicine flexibilities, extended through December 31, 2026, let registered practitioners prescribe controlled medications remotely without an in-person evaluation, but they lift no state limit — an Oklahoma Schedule II stimulant is as un-prescribable by video as on paper.

Oklahoma has not enacted the APRN Compact.

The compact takes effect only once seven states enact it, and as of September 2026 five had (Delaware, North Dakota, South Dakota, Utah and Wyoming), so no APRN holds a multistate APRN licence today.

The Nurse Licensure Compact does surface once in Oklahoma's own paperwork: the Board accepts an active multistate RN licence from another compact state, with Oklahoma multistate licensure privilege, as the RN foundation under an application (Form RS-07b).

The APRN licence, the recognition and any independent authority remain Oklahoma-specific.

Laws 2025, c.

340, effective November 1, 2025, added § 567.4c — the 6,240-hour independent route — and amended § 567.3a and § 567.4a.

The enacting bill number was not located in the sources read, so cite the act, not a bill number.

The 2025 edition of 63 O.S. § 2-312 could not be retrieved (Cloudflare blocked the page), so no post-act statutory text for the controlled-substances provision was read; the Board's post-act documents — the September 30, 2025 formulary and the October 30, 2025 independent-authority form — both still bar Schedule I and II.

Prescriptive authority carries its own education track.

Initial recognition requires at least forty-five (45) contact hours or three (3) academic credit hours of pharmacotherapeutics education obtained within the three years before application; the window may be waived for a recent graduate whose program incorporated didactic and clinical preparation for prescribing throughout (§ 567.4a(3); OAC 485:10-16-3(4)).

Renewal of the base recognition requires fifteen (15) contact hours or one (1) academic credit hour of pharmacotherapeutics plus two (2) hours in pain management or opioid use or addiction — the latter two hours waived when the APRN demonstrates to the Board's satisfaction that they hold no valid federal DEA registration number (§ 567.4a(4)); under the rules, the pharmacotherapeutics documentation alone is excused for a renewal within twenty-four (24) months of initial prescriptive authority approval — the two pain/opioid hours still apply (OAC 485:10-16-6(2)(B)).

Independent-authority renewal adds the forty (40) Category I continuing medical education hours, which may include that education where it meets Category I criteria.

The statute requires annual Board and Formulary Advisory Council review of the exclusionary formulary (§ 567.4a(10)).